Abeona Expands ZEVASKYN Access with New Treatment Center in New York
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2026
0mins
Should l Buy ABEO?
Source: Newsfilter
- Treatment Center Expansion: Abeona Therapeutics has activated the NewYork-Presbyterian/Columbia University Irving Medical Center as its fifth Qualified Treatment Center, significantly enhancing patient access to ZEVASKYN and expected to improve treatment experiences for RDEB patients in the Northeast.
- Clinical Expertise Support: Partnering with a globally recognized institution in genetic medicine ensures that patients receive world-class clinical support throughout their treatment journey, which not only enhances treatment efficacy but also boosts patient confidence and hope.
- Innovative Treatment Solution: ZEVASKYN is the first autologous cell-based gene therapy for treating wounds in RDEB patients, utilizing COL7A1 gene modification technology, which has demonstrated significant wound healing and pain reduction, potentially transforming patients' quality of life.
- Patient Support Program: Abeona Assist offers personalized support, including understanding insurance benefits and financial assistance, aimed at alleviating the economic burden on patients during treatment, thereby improving treatment adherence and satisfaction.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABEO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABEO
Wall Street analysts forecast ABEO stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.500
Low
20.00
Averages
25.17
High
28.00
Current: 5.500
Low
20.00
Averages
25.17
High
28.00
About ABEO
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abeona Therapeutics Appoints New Board Member
- New Board Member: Abeona Therapeutics appointed Keith A. Goldan as an independent director effective April 1, 2026, also serving as Chairman of the Audit Committee, aiming to strengthen governance through his extensive financial leadership experience.
- Financial Leadership Experience: Goldan brings over 20 years of financial management experience in biotechnology and specialty pharmaceutical companies, having served as CFO at Syndax Pharmaceuticals where he led two product approvals and commercialization, which is expected to significantly support Abeona's strategic objectives.
- Strategic Growth Period: Goldan expressed excitement about joining Abeona during this critical growth phase, looking forward to collaborating with the leadership team to advance strategic priorities and drive value for patients and shareholders, reflecting the company's confidence in future development.
- Product Development and Market Opportunities: Abeona is developing cell and gene therapies for serious diseases, with its first product ZEVASKYN® being the only autologous cell-based gene therapy for a specific skin condition, and Goldan's addition is anticipated to enhance the product's commercialization potential.
See More
Abeona Therapeutics Grants Equity Awards to New Employees
- Equity Award Program: On March 31, 2026, Abeona Therapeutics granted 8,400 restricted shares to four new non-executive employees as a material inducement for employment, reflecting the company's commitment to attracting top talent.
- Vesting Schedule: The equity awards will vest one-third annually on each anniversary of the grant date, ensuring employee retention over three years, which enhances loyalty and stability within the workforce.
- Company Overview: Abeona is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases, with its ZEVASKYN® being the first autologous cell-based gene therapy for treating severe skin conditions, indicating significant market potential.
- Manufacturing Capability: The company's cGMP manufacturing facility in Cleveland, Ohio supports the commercial production of ZEVASKYN, ensuring the ability to meet market demand and enhancing the company's competitiveness in the gene therapy sector.
See More
Abeona Expands ZEVASKYN Access with New Treatment Center in New York
- Treatment Center Expansion: Abeona Therapeutics has activated the NewYork-Presbyterian/Columbia University Irving Medical Center as its fifth Qualified Treatment Center, significantly enhancing patient access to ZEVASKYN and expected to improve treatment experiences for RDEB patients in the Northeast.
- Clinical Expertise Support: Partnering with a globally recognized institution in genetic medicine ensures that patients receive world-class clinical support throughout their treatment journey, which not only enhances treatment efficacy but also boosts patient confidence and hope.
- Innovative Treatment Solution: ZEVASKYN is the first autologous cell-based gene therapy for treating wounds in RDEB patients, utilizing COL7A1 gene modification technology, which has demonstrated significant wound healing and pain reduction, potentially transforming patients' quality of life.
- Patient Support Program: Abeona Assist offers personalized support, including understanding insurance benefits and financial assistance, aimed at alleviating the economic burden on patients during treatment, thereby improving treatment adherence and satisfaction.
See More
Abeona Therapeutics Q4 2025 Earnings Call Highlights
- Growing Patient Demand: Following the launch of ZEVASKYN in Q4 2025, the number of eligible patients surged from nearly 50 to over 100, indicating strong market demand that is expected to drive revenue growth and enhance competitive positioning.
- Improved Financial Performance: Total revenue for 2025 reached $5.8 million, with product revenue at $2.4 million and net income of $71.2 million, marking a shift from previous net losses to profitability, reflecting the effectiveness of the company's business model and market acceptance.
- Decreased R&D Spending: R&D expenses fell to $26.8 million in 2025 from $34.4 million in 2024, a reduction of $7.6 million primarily due to the FDA approval of ZEVASKYN and the subsequent shift of certain costs to inventory, showcasing the company's success in cost management.
- Expansion Plans: Management aims to activate at least 7 qualified treatment centers by the end of 2026 to ensure geographic coverage expansion, with expectations that treating over 3 patients per month will lead the company into profitability, further solidifying its market position.
See More
Abeona Therapeutics Launches Zivasskin Therapy Amid Growing Demand
- Growing Patient Demand: Abeona Therapeutics has seen increasing demand for Zivasskin, the first autologous cell-based gene therapy for RDE, with plans to ramp up its launch in 2026, enhancing its market share in the rare disease sector.
- Insurance Coverage Policies: Major commercial payers, including UnitedHealthcare and Cigna, have published coverage policies for Zivasskin, facilitating quicker patient access to treatment and potentially driving sales growth.
- Strong Financial Performance: The company recorded a $152.4 million gain from the sale of its rare pediatric disease priority review voucher, contributing to a net income of $71.2 million for 2025, reflecting a solid financial foundation and future growth potential.
- Operational Challenges: Despite the positive outlook for Zivasskin's launch, the lengthy onboarding process for Qualified Treatment Centers and variability in production timelines may hinder timely patient treatment, necessitating improvements in operational efficiency to meet market demand.
See More
Abeona (ABEO) Q4 2025 Earnings Call Transcript
See More
Abeona Therapeutics Appoints New Board Member
- New Board Member: Abeona Therapeutics appointed Keith A. Goldan as an independent director effective April 1, 2026, also serving as Chairman of the Audit Committee, aiming to strengthen governance through his extensive financial leadership experience.
- Financial Leadership Experience: Goldan brings over 20 years of financial management experience in biotechnology and specialty pharmaceutical companies, having served as CFO at Syndax Pharmaceuticals where he led two product approvals and commercialization, which is expected to significantly support Abeona's strategic objectives.
- Strategic Growth Period: Goldan expressed excitement about joining Abeona during this critical growth phase, looking forward to collaborating with the leadership team to advance strategic priorities and drive value for patients and shareholders, reflecting the company's confidence in future development.
- Product Development and Market Opportunities: Abeona is developing cell and gene therapies for serious diseases, with its first product ZEVASKYN® being the only autologous cell-based gene therapy for a specific skin condition, and Goldan's addition is anticipated to enhance the product's commercialization potential.
See More
Abeona Therapeutics Grants Equity Awards to New Employees
- Equity Award Program: On March 31, 2026, Abeona Therapeutics granted 8,400 restricted shares to four new non-executive employees as a material inducement for employment, reflecting the company's commitment to attracting top talent.
- Vesting Schedule: The equity awards will vest one-third annually on each anniversary of the grant date, ensuring employee retention over three years, which enhances loyalty and stability within the workforce.
- Company Overview: Abeona is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases, with its ZEVASKYN® being the first autologous cell-based gene therapy for treating severe skin conditions, indicating significant market potential.
- Manufacturing Capability: The company's cGMP manufacturing facility in Cleveland, Ohio supports the commercial production of ZEVASKYN, ensuring the ability to meet market demand and enhancing the company's competitiveness in the gene therapy sector.
See More
Abeona Expands ZEVASKYN Access with New Treatment Center in New York
- Treatment Center Expansion: Abeona Therapeutics has activated the NewYork-Presbyterian/Columbia University Irving Medical Center as its fifth Qualified Treatment Center, significantly enhancing patient access to ZEVASKYN and expected to improve treatment experiences for RDEB patients in the Northeast.
- Clinical Expertise Support: Partnering with a globally recognized institution in genetic medicine ensures that patients receive world-class clinical support throughout their treatment journey, which not only enhances treatment efficacy but also boosts patient confidence and hope.
- Innovative Treatment Solution: ZEVASKYN is the first autologous cell-based gene therapy for treating wounds in RDEB patients, utilizing COL7A1 gene modification technology, which has demonstrated significant wound healing and pain reduction, potentially transforming patients' quality of life.
- Patient Support Program: Abeona Assist offers personalized support, including understanding insurance benefits and financial assistance, aimed at alleviating the economic burden on patients during treatment, thereby improving treatment adherence and satisfaction.
See More
Abeona Therapeutics Q4 2025 Earnings Call Highlights
- Growing Patient Demand: Following the launch of ZEVASKYN in Q4 2025, the number of eligible patients surged from nearly 50 to over 100, indicating strong market demand that is expected to drive revenue growth and enhance competitive positioning.
- Improved Financial Performance: Total revenue for 2025 reached $5.8 million, with product revenue at $2.4 million and net income of $71.2 million, marking a shift from previous net losses to profitability, reflecting the effectiveness of the company's business model and market acceptance.
- Decreased R&D Spending: R&D expenses fell to $26.8 million in 2025 from $34.4 million in 2024, a reduction of $7.6 million primarily due to the FDA approval of ZEVASKYN and the subsequent shift of certain costs to inventory, showcasing the company's success in cost management.
- Expansion Plans: Management aims to activate at least 7 qualified treatment centers by the end of 2026 to ensure geographic coverage expansion, with expectations that treating over 3 patients per month will lead the company into profitability, further solidifying its market position.
See More
Abeona Therapeutics Launches Zivasskin Therapy Amid Growing Demand
- Growing Patient Demand: Abeona Therapeutics has seen increasing demand for Zivasskin, the first autologous cell-based gene therapy for RDE, with plans to ramp up its launch in 2026, enhancing its market share in the rare disease sector.
- Insurance Coverage Policies: Major commercial payers, including UnitedHealthcare and Cigna, have published coverage policies for Zivasskin, facilitating quicker patient access to treatment and potentially driving sales growth.
- Strong Financial Performance: The company recorded a $152.4 million gain from the sale of its rare pediatric disease priority review voucher, contributing to a net income of $71.2 million for 2025, reflecting a solid financial foundation and future growth potential.
- Operational Challenges: Despite the positive outlook for Zivasskin's launch, the lengthy onboarding process for Qualified Treatment Centers and variability in production timelines may hinder timely patient treatment, necessitating improvements in operational efficiency to meet market demand.
See More
Abeona (ABEO) Q4 2025 Earnings Call Transcript
See More
